RAD-140 (Testolone)
Aliases: Testolone · Vosilasarm
Last verified: 2026-09-23
The short version
A strong SARM with neuroprotective potential (preclinical); in clinical development for AR+ breast cancer. A favorite for mass/strength. Status: in clinical trials. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A strong SARM with neuroprotective potential (preclinical); in clinical development for AR+ breast cancer.
Mechanism of action
Selective AR agonism; high anabolic:androgenic ratio preclinically.
Dosing & routes
Official / clinical context
No approved official document exists for RAD-140 (Testolone). Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Community: 10–20 mg/day for 8 weeks; early-phase trials. Strong strength gains and dry mass are reported, with a more "aggressive" training feel; some users report headaches and liver-enzyme elevation. Considered the strongest popular SARM.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Strong strength gains and dry mass are reported, with a more "aggressive" training feel; some users report headaches and liver-enzyme elevation. Considered the strongest popular SARM.
Protocol — official vs community
Official / label
No approved product. Human data limited to a phase 1 (up to 100 mg single dose) and a terminated breast-cancer study.
- 01Phase 1 explored up to 100 mg
Duration: Study-defined.
Testolone's reputation for potency exceeds its formal human data.
Community (anecdotal)
10–20 mg oral daily (some 'experienced' listings go to 30 mg).
- Cycle:
- 8 weeks.
- Break:
- 8+ weeks with PCT.
Anecdotally the harshest of the mainstream SARMs for suppression and aggression sides.
Human evidence
Phase I/II in AR+ HER2− breast cancer.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Suppression, aggression in some, liver-enzyme elevation, rare idiosyncratic hepatotoxicity (case reports).characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.